Newsroom
Strive to Deliver Breakthroughs
-
August 09, 2022
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022
Cambridge, MA, Rotterdam, NL, Suzhou, CN – Aug 9, 2022 Harbour BioMed (the “Company”, HKEX: 02142) announced that it will repor...
View more -
August 08, 2022
PNAS Published Preclinical Results of Harbour BioMed’s Next-Generation Fully Human Heavy-chain Antibody Porustobart
Cambridge, MA, Rotterdam, NL, Suzhou, CN— Aug 8, 2022 Harbour BioMed (the “Company”, HKEX: 02142) announced that the preclinica...
View more -
June 27, 2022
Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration
Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 27, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that the U.S. Food and Dr...
View more -
June 08, 2022
Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN — June 8, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that China National Medica...
View more -
June 01, 2022
Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism
Cambridge, MA, Rotterdam, NL, Suzhou, CN — Jun 1, 2022 Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical ...
View more -
May 25, 2022
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 25, 2022 Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successfully ...
View more -
May 10, 2022
Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting
Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 10, 2022 Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical...
View more -
May 06, 2022
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board
Cambridge, MA, Rotterdam, NL, Suzhou, CN — May 6, 2022 Harbour BioMed (“HBM”, HKEX:02142), a global biopharmaceutical company co...
View more -
April 14, 2022
Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer
CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - April 14, 2022 Harbour BioMed (“HBM” or the “Company”; HKEX: 021...
View more -
April 07, 2022
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
Cambridge, MA, Rotterdam, NL, Suzhou, CN— April 7, 2022 Harbour BioMed (“HBM”, “the Company”, HKEX: 02142), a globa...
View more
Copyright © 2022 Harbour BioMed. All Rights Reserved 沪ICP备19015946号-1